Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Scott Hoyt"'
Autor:
LaQuita Jones, Katelyn Melgar, Scott Hoyt, Mark Wunderlich, Eric O’Brien, John Perentesis, Craig Thomas, Daniel Starczynowski
Publikováno v:
Journal of Clinical and Translational Science, Vol 5, Pp 100-100 (2021)
ABSTRACT IMPACT: This work will help to understand a novel therapeutic approach to a common type of acute myeloid leukemia. OBJECTIVES/GOALS: FMS-like tyrosine kinase 3 (or FLT3) mutations occur in ˜30% of acute myeloid leukemia (AML) cases. FLT3 ty
Externí odkaz:
https://doaj.org/article/7c57bb80a91b4c35bb32004d31b249b8
Publikováno v:
PLoS ONE, Vol 10, Iss 3, p e0122012 (2015)
Insulin resistance is the key feature of type 2 diabetes and is manifested as attenuated insulin receptor (IR) signaling in response to same levels of insulin binding. Several small molecule IR activators have been identified and reported to exhibit
Externí odkaz:
https://doaj.org/article/180826ff9bef4585b00a3806018c4937
Autor:
Joshua Ruina Bennett, Chiharu Ishikawa, Puneet Agarwal, Jennifer Yeung, Avery Sampson, Emma Uible, Eric Vick, Lyndsey Bolanos, Kathleen M Hueneman, Mark Wunderlich, Amal Kolt, Kwangmin Choi, Andrew G Volk, Kenneth D Greis, Jan S. Rosenbaum, Scott Hoyt, Craig J Thomas, Daniel T Starczynowski
Publikováno v:
Blood Journal.
Dysregulation of innate immune signaling is a hallmark of hematologic malignancies. Recent therapeutic efforts to subvert aberrant innate immune signaling in MDS and AML have focused on the kinase IRAK4. IRAK4 inhibitors have achieved promising, thou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b556cf67bef65c7d2de75fe57ee9811
https://doi.org/10.1182/blood.2022018718
https://doi.org/10.1182/blood.2022018718
Autor:
Craig J. Thomas, Patrick Sutter, Katelyn Melgar, Morgan M. Walker, Lyndsey Bolanos, Xin Xu, Jian-kang Jiang, Kelli M. Wilson, Mark Wunderlich, LaQuita M Jones, Gregory J. Tawa, Xiaohu Zhang, Scott Hoyt, John P. Perentesis, Kathleen Hueneman, Eric O'Brien, Jian Shen, Amy Wang, Fan Jiang, Daniel T. Starczynowski
Publikováno v:
J Clin Invest
Tyrosine kinase domain (TKD) mutations contribute to acquired resistance to FMS-like tyrosine kinase 3 (FLT3) inhibitors used to treat FLT3-mutant acute myeloid leukemia (AML). We report a cocrystal structure of FLT3 with a type I inhibitor, NCGC1481
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24e888dffa439b033f1f8aea3abfe314
https://doi.org/10.1172/jci127907
https://doi.org/10.1172/jci127907
Autor:
Katelyn Melgar, Craig J. Thomas, Eric O'Brien, Scott Hoyt, John P. Perentesis, LaQuita M Jones, Mark Wunderlich, Daniel T. Starczynowski
Publikováno v:
Journal of Clinical and Translational Science. 5:100-100
IMPACT: This work will help to understand a novel therapeutic approach to a common type of acute myeloid leukemia. OBJECTIVES/GOALS: FMS-like tyrosine kinase 3 (or FLT3) mutations occur in ˜30% of acute myeloid leukemia (AML) cases. FLT3 tyrosine ki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::506fe96e6b10145f769eebb95e0b82f7
https://doi.org/10.1017/cts.2021.658
https://doi.org/10.1017/cts.2021.658
Autor:
Michele Ceribelli, Patrick J. Morris, Damien Y. Duveau, Frances A. Tosto, Scott Hoyt, Craig J. Thomas
Publikováno v:
Molecular Cancer Research. 18:B06-B06
We performed a large-scale profiling of currently available kinase inhibitors (KI) to identify “off-targets” that could be repurposed/repositioned as the starting point for the rational development of novel and selective kinase inhibitors against
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::84d747450823b22cd217e73a1420434f
https://doi.org/10.1158/1557-3125.hippo19-b06
https://doi.org/10.1158/1557-3125.hippo19-b06
Autor:
Kathleen Hueneman, Morgan M. Walker, Patrick Sutter, Xiaohu Zhang, Xin Xu, Mark Wunderlich, Donald D. Lorimer, Jan Abendroth, James C. Mulloy, Eric O'Brien, LaQuita M Jones, Christopher Famulare, Ross L. Levine, Lyndsey Bolanos, Katelyn Melgar, Amy Wang, Kwangmin Choi, Scott Hoyt, Daniel T. Starczynowski, Jiang-Kang Jiang, Ellin Berman, Craig J. Thomas, Gregory J. Tawa, John P. Perentesis, Kelli M. Wilson
Publikováno v:
Ann Transl Med
Targeted inhibitors to oncogenic kinases demonstrate encouraging clinical responses early in the treatment course, however, most patients will relapse due to target-dependent mechanisms that mitigate enzyme-inhibitor binding or through target-indepen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df7b9ca1733ed4e8eb35cba075a37f32
https://doi.org/10.1182/blood-2019-124178
https://doi.org/10.1182/blood-2019-124178
Publikováno v:
ChemInform. 23
The stereospecific synthesis of a cis -syn pyrimidine photodimer has been achieved using a cleavable linker. Removal of the linker is accomplished via bromine addition followed by a dual retro-Michael reaction.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e72af64e2851422013e858b82eb9016
https://doi.org/10.1002/chin.199243189
https://doi.org/10.1002/chin.199243189
Publikováno v:
Tetrahedron Letters. 33:2133-2136
The stereospecific synthesis of a cis -syn pyrimidine photodimer has been achieved using a cleavable linker. Removal of the linker is accomplished via bromine addition followed by a dual retro-Michael reaction.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e76f7af29a5750b20a340b86c28cb2f
https://doi.org/10.1016/0040-4039(92)88159-3
https://doi.org/10.1016/0040-4039(92)88159-3
Autor:
Scott, Hoyt S.
Publikováno v:
Transactions of the American Institute of Electrical Engineers; 1949, Vol. 68 Issue 1, p725-729, 5p